Committed to putting asthma patients in better control
Areteia Therapeutics was a clinical-stage biotechnology company developing dexpramipexole, an oral eosinophil-maturation inhibitor, to treat eosinophilic asthma and put patients back in control of their disease. Focused on novel inflammation and immunology therapies, it raised $425M in funding led by ARCH Venture Partners and GV. The company wound down operations in late 2025 amid Phase 3 drug trials.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2024
Jul 2022
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
